Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
- Trial name
- NCT03934541
- Testing
- MPER-656 Liposome Vaccine
- Where
- 6 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV Antiretroviral Therapy (ART) Adherence
Transitional Housing and HIV Health
The goal of this pilot study is to evaluate the implementation and outcomes of the Arms Around You (AAY) program, a supportive housing initiative launched by the Philadelphia Department of Public Health (PDPH) in 2024.
- Conditions
- HIV, HIV Antiretroviral Therapy (ART) Adherence, Housing Instability
- Trial name
- NCT06829394
- Testing
- Program Assignment
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Pennsylvania
HIV Infections
PREventing Progression of Adipose Tissue Redistribution
The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either…
- Trial name
- NCT00389194
- Testing
- continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
HIV Infections
The St. Marys and The Mater Switch Study
The aim of the study is to determine whether switching from an antiretroviral regimen containing abacavir and/or didanosine to one containing maraviroc will lead to a reduction in platelet reactivity and inflammatory markers at…
- Trial name
- SMASH (NCT00981773)
- Testing
- Maraviroc
- Where
- 3 sites in Ireland, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Imperial College London
HIV Infections
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
This study will test the safety and immunogenicity of the gp120/NefTat/AS02A vaccine candidate in individuals with chronic HIV-1 infection successfully treated with HAART.
- Trial name
- NCT00117429
- Testing
- HIV gp120/NefTat/AS02A Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Marcus Altfeld, M.D., Ph.D.
HIV Infections
A Study of 1592U89 in HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
- Trial name
- NCT00002200
- Testing
- Abacavir sulfate
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV-1-infection
Quality of Life of Taiwan People Living With HIV
To survey QoL and relevant factors in PLWH
- Trial name
- NCT04063306
- Testing
- none of intervention was given
- Where
- Taiwan
- Volunteers
- 550 people
- Sponsor
- Taiwan AIDS Nurse Society
HIV-1 Infection
MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-retroviral therapy (ART) activity of the tenofovir prodrug, MK-8583 monotherapy in ART-naïve, HIV-1 infected participants.
- Trial name
- NCT03552536
- Testing
- MK-8583
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
The purpose of this study is to determine the antiviral activity, safety and tolerability of TMC114, formulated as an oral tablet, and administered with a low dose of ritonavir
- Trial name
- NCT00650832
- Testing
- TMC114; darunavir; Prezista
- Volunteers
- 334 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression
An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART regimen with persistent HIV-1 viral suppression could increase the slope of decay of the HIV-1 latent reservoir.
- Trial name
- NCT00554398
- Testing
- MK-0518 400mg twice a day
- Where
- 3 sites in Spain
- Volunteers
- 69 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV-1 Infection
Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women
This study was done to look at the level of Depo-Provera, an injectable birth control, in the blood to see whether it is affected by the anti-HIV drug Kaletra (lopinavir/ritonavir [LPV/r]).
- Trial name
- NCT01296152
- Testing
- depo-medroxyprogesterone acetate
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 25 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1 Infection, AIDS
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
The objective of the OPTIMAL study is to demonstrate that the adjunction of Maraviroc to a combination of antiretroviral therapy in naive and late diagnosed HIV-1 infected patients counts may accelerate the kinetics of immune…
- Trial name
- OPTIMAL (NCT01348308)
- Testing
- Maraviroc (Celsentri)
- Where
- France
- Volunteers
- 407 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine…
- Trial name
- NCT05495204
- Testing
- Ibalizumab
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Epividian
HIV-1-infection
ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance
This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological…
- Trial name
- ADORE (NCT04429152)
- Testing
- Doravirine/Lamivudine/Tenofovir
- Where
- 3 sites in South Africa
- Volunteers
- 25 people
- Sponsor
- Professor Francois Venter
HIV-1 Infection
Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
The purpose of this study was to see which one of two medicines (topical gentian violet [GV] or nystatin oral suspension) was better than the other in treating Oral Candidiasis (OC).
- Trial name
- NCT01427738
- Testing
- Gentian Violet, Nystatin oral suspension
- Where
- 10 sites in Botswana, India and 5 more
- Volunteers
- 221 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections, HIV-1
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible…
- Trial name
- NCT00980538
- Testing
- Etravirine
- Where
- 29 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Janssen Sciences Ireland UC
HIV
Renal Integrase Study
The purpose of this study is to observe the safety of Truvada® (TDF/FTC) in relation to its impact on kidney function combined with different Integrase Inhibitors (Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir), when…
- Trial name
- NCT02351908
- Testing
- Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat), Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet, Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- St Stephens Aids Trust
HIV-1
HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen
The purpose of this study is to assess changes in viral reservoir after changing IP/r to dolutegravir in HIV-1 infected patients maintaining undetectable viral load on Antiretroviral Therapy (ART).
- Trial name
- NCT02513147
- Testing
- Dolutegravir, PI, 2 NRTI
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
HIV Infections
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.
- Trial name
- NCT00004985
- Testing
- Capravirine, Nelfinavir mesylate
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Agouron Pharmaceuticals
HIV
Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals
The HIVconsv gene was constructed by assembling the 14 most conserved regions of the HIV-1 proteome into one chimaeric protein. This gene has been inserted into 2 leading non-replicating vaccine vectors: an attenuated chimpanzee…
- Trial name
- NCT01712425
- Testing
- 0-24 week prime/boost regimen, 0-8 week prime/boost regimen
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- IrsiCaixa
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.